Alexis Vogelzang

Alexis Vogelzang

Auto-generated profile, based on publicly available information

Alexis Vogelzang

Laboratory for Mucosal Immunity, Center for Integrative Medical Sciences, RIKEN Yokohama Institute, Yokohama, Japan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in Immunity
Verified
Journal Article
Closed access
AVAlexis Vogelzang
Alexis Vogelzang
HMHelen M. McGuire
Helen M. McGuire
DYDi Yu
Di Yu
JSJonathan Sprent
Jonathan Sprent
CMCharles R. Mackay
Charles R. Mackay
Cecile KingCecile King
Cecile King

24 July 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ANAkira Nakajima
Akira Nakajima
AVAlexis Vogelzang
Alexis Vogelzang
MMMikako Maruya
Mikako Maruya
MMMichio Miyajima
Michio Miyajima
MMMegumi Murata
Megumi Murata
KSKeiichiro Suzuki
Keiichiro Suzuki
Immunoglobulin A (IgA) promotes health by regulating the composition and function of gut microbiota, but the molecular requirements for such homeostatic IgA function remain unknown. We found that a heavily glycosylated monoclonal IgA recognizing ovalbumin coats Bacteroides thetaiotaomicron (B. theta), a prominent gut symbiont of the phylum Bacteroidetes. In vivo, IgA alters the expression of polysaccharide utilization loci (PUL), including a functionally uncharacterized molecular family provisionally named Mucus-Associated Functional Factor (MAFF). In both mice and humans, MAFF is detected predominantly in mucus-resident bacteria, and its expression requires the presence of complex microbiota. Expression of the MAFF system facilitates symbiosis with other members of the phylum Firmicutes and promotes protection from a chemically induced model of colitis. Our data reveal a novel mechanism by which IgA promotes symbiosis and colonic homeostasis.

30 December 2016 in mBio
Verified
Journal Article
Open access
PDF file
CPCarolina Perdomo
Carolina Perdomo
UZUlrike Zedler
Ulrike Zedler
AKAnja A Kühl
Anja A Kühl
LLLaura Lozza
Laura Lozza
PSPhilippe Saikali
Philippe Saikali
AKAndreas Kupz
Andreas Kupz
Mycobacterium bovis Bacille Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB), yet its moderate efficacy against pulmonary TB calls for improved vaccination strategies. Mucosal BCG vaccination generates superior protection against TB in animal models; however, the mechanisms of protection remain elusive. Tissue-resident memory T (T RM ) cells have been implicated in protective immune responses against viral infections, but the role of T RM cells following mycobacterial infection is unknown. Using a mouse model of TB, we compared protection and lung cellular infiltrates of parenteral and mucosal BCG vaccination. Adoptive transfer and gene expression analyses of lung airway cells were performed to determine the protective capacities and phenotypes of different memory T cell subsets. In comparison to subcutaneous vaccination, intratracheal and intranasal BCG vaccination generated T effector memory and T RM cells in the lung, as defined by surface marker phenotype. Adoptive mucosal transfer of these airway-resident memory T cells into naive mice mediated protection against TB. Whereas airway-resident memory CD4 + T cells displayed a mixture of effector and regulatory phenotype, airway-resident memory CD8 + T cells displayed prototypical T RM features. Our data demonstrate a key role for mucosal vaccination-induced airway-resident T cells in the host defense against pulmonary TB. These results have direct implications for the design of refined vaccination strategies. IMPORTANCE BCG remains the only licensed vaccine against TB. Parenterally administered BCG has variable efficacy against pulmonary TB, and thus, improved prevention strategies and a more refined understanding of correlates of vaccine protection are required. Induction of memory T cells has been shown to be essential for protective TB vaccines. Mimicking the natural infection route by mucosal vaccination has been known to generate superior protection against TB in animal models; however, the mechanisms of protection have remained elusive. Here we performed an in-depth analysis to dissect the immunological mechanisms associated with superior mucosal protection in the mouse model of TB. We found that mucosal, and not subcutaneous, BCG vaccination generates lung-resident memory T cell populations that confer protection against pulmonary TB. We establish a comprehensive phenotypic characterization of these populations, providing a framework for future vaccine development.

10 February 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
GNGeraldine Nouailles
Geraldine Nouailles
ADAnca Dorhoi
Anca Dorhoi
MKMarkus Koch
Markus Koch
JZJens Zerrahn
Jens Zerrahn
JWJanuary Weiner
January Weiner
SKStefan H.E. Kaufmann
Stefan H.E. Kaufmann
Successful host defense against numerous pulmonary infections depends on bacterial clearance by polymorphonuclear leukocytes (PMNs); however, excessive PMN accumulation can result in life-threatening lung injury. Local expression of CXC chemokines is critical for PMN recruitment. The impact of chemokine-dependent PMN recruitment during pulmonary Mycobacterium tuberculosis infection is not fully understood. Here, we analyzed expression of genes encoding CXC chemokines in M. tuberculosis–infected murine lung tissue and found that M. tuberculosis infection promotes upregulation of Cxcr2 and its ligand Cxcl5. To determine the contribution of CXCL5 in pulmonary PMN recruitment, we generated Cxcl5–/– mice and analyzed their immune response against M. tuberculosis. Both Cxcr2–/– mice and Cxcl5–/– mice, which are deficient for only one of numerous CXCR2 ligands, exhibited enhanced survival compared with that of WT mice following high-dose M. tuberculosis infection. The resistance of Cxcl5–/– mice to M. tuberculosis infection was not due to heightened M. tuberculosis clearance but was the result of impaired PMN recruitment, which reduced pulmonary inflammation. Lung epithelial cells were the main source of CXCL5 upon M. tuberculosis infection, and secretion of CXCL5 was reduced by blocking TLR2 signaling. Together, our data indicate that TLR2-induced epithelial-derived CXCL5 is critical for PMN-driven destructive inflammation in pulmonary tuberculosis.

29 April 2014 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
ADAnca Dorhoi
Anca Dorhoi
Vladimir YeremeevVladimir Yeremeev
Vladimir Yeremeev
GNGeraldine Nouailles
Geraldine Nouailles
JWJanuary Weiner
January Weiner
SJSabine Jörg
Sabine Jörg
SKStefan H.E. Kaufmann
Stefan H.E. Kaufmann
General interest in the biological functions of IFN type I inMycobacterium tuberculosis(Mtb) infection increased after the recent identification of a distinct IFN gene expression signature in tuberculosis (TB) patients. Here, we demonstrate that TB‐susceptible mice lacking the receptor for IFN I (IFNAR1) were protected from death upon aerogenic infection with Mtb. Using this experimental model to mimic primary progressive pulmonary TB, we dissected the immune processes affected by IFN I. IFNAR1 signaling did not affect T‐cell responses, but markedly altered migration of inflammatory monocytes and neutrophils to the lung. This process was orchestrated by IFNAR1 expressed on both immune and tissue‐resident radioresistant cells. IFNAR1‐driven TB susceptibility was initiated by augmented Mtb replication and in situ death events, along with CXCL5/CXCL1‐driven accumulation of neutrophils in alveoli, followed by the discrete compartmentalization of Mtb in lung phagocytes. Early depletion of neutrophils rescued TB‐susceptible mice to levels observed in mice lacking IFNAR1. We conclude that IFN I alters early innate events at the site of Mtb invasion leading to fatal immunopathology. These data furnish a mechanistic explanation for the detrimental role of IFN I in pulmonary TB and form a basis for understanding the complex roles of IFN I in chronic inflammation.

18 June 2014 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
AVAlexis Vogelzang
Alexis Vogelzang
CPCarolina Perdomo
Carolina Perdomo
UZUlrike Zedler
Ulrike Zedler
SKStefanie Kuhlmann
Stefanie Kuhlmann
RHRobert Hurwitz
Robert Hurwitz
SKStefan H.E. Kaufmann
Stefan H.E. Kaufmann
Bacillus Calmette-Guérin (BCG) has been used for vaccination against tuberculosis for nearly a century. Here, we analyze immunity induced by a live tuberculosis vaccine candidate, recombinant BCG ΔureC::hly vaccine (rBCG), with proven preclinical and clinical safety and immunogenicity. We pursue in-depth analysis of the endogenous mycobacteria-specific CD4+ T-cell population, comparing the more efficacious rBCG with canonical BCG to determine which T-cell memory responses are prerequisites for superior protection against tuberculosis. rBCG induced higher numbers and proportions of antigen-specific memory CD4+ T cells than BCG, with a CXCR5+CCR7+ phenotype and low expression of the effector transcription factors T-bet and Bcl-6. We found that the superior protection of rBCG, compared with BCG, correlated with higher proportions and numbers of these central memory T cells and of T follicular helper cells associated with specific antibody responses. Adoptive transfer of mycobacteria-specific central memory T cells validated their critical role in protection against pulmonary tuberculosis.